GlassScriptPhysician profile
Mitra Haeri
NPI 1356846315
$7,347.44
in general payments reported to CMS, 2019-2025
19 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $481 · 2023: $1,030 · 2024: $3,655 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,574 · Consulting Fee: $1,276 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,573.77 |
| Consulting Fee | $1,275.75 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,472.99 | 2022-2025 | |
| Pfizer INC. | $1,180.61 | 2024-2025 | |
| Axsome Therapeutics, INC. | $504.61 | 2024-2025 | Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $486.38 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $462.29 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $360.92 | 2023-2024 | Emgality, Reyvow, Kisunla |
| Lundbeck LLC | $282.78 | 2023-2025 | Vyepti |
| Ucb, INC. | $99.57 | 2024 | Rystiggo |
| Genentech USA, INC. | $97.59 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $69.52 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.04 | 2022 | |
| Grifols USA, LLC | $46.48 | 2024 | Gamunex-C |
| Impel Pharmaceuticals LLC | $45.38 | 2024-2025 | Trudhesa |
| Biogen, INC. | $42.90 | 2025 | Leqembi, Tysabri |
| Banner Life Sciences, LLC | $38.22 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $31.08 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $30.48 | 2025 | Ultomiris |
| Vanda Pharmaceuticals INC. | $27.47 | 2024 | Ponvory |
| Upsher-Smith Laboratories LLC | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Haeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.